Pharma BD Deal Intelligence
Jazz Pharmaceuticals' acquisition of GW Pharmaceuticals closes, creating an innovative, high-growth global biopharma leader with a diversified portfolio…
Jazz acquired GW Pharmaceuticals for $7.2B for Epidiolex (cannabidiol) for epilepsy.
Epidiolex/Epidyolex achieved blockbuster status in 2025 with net product sales increasing 9% to $1.1 billion in 2025.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Jazz acquired GW Pharmaceuticals for $7.2B for Epidiolex (cannabidiol) for epilepsy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals (this deal) | 2021 | $7.2B | 77 |
| Jazz Pharmaceuticals PLC / Celator Pharmaceuticals | 2016 | $1.5B | 73 |
| Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. | 2026 | $848M | 50 |
| Jazz Pharmaceuticals PLC / Chimerix, Inc. | 2025 | $935M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2021 deals · Jazz Pharmaceuticals PLC deals · Neurology deals